MICHAEL F. HALLER, PH.D.
Chief Business Officer
Dr. Haller is Peloton Therapeutics’ Chief Business Officer. Prior to Peloton, he was Chief Operating Officer at Denovo Biomarkers and Vice President, Business Development at GlyTech, where he led business development efforts and strategy. Dr. Haller has been Vice President of Business Development and Alliance Management at Ligand Pharmaceuticals and Senior Vice President of Strategic Partnerships at Anaphore. He joined Anaphore from Halozyme Therapeutics, where he was an early employee. As Vice President of Alliance Management and Head, Drug Delivery Franchise, he helped grow Halozyme into a $1B market cap company through key partnerships with Roche and Baxter Healthcare. Prior to Halozyme, Dr. Haller was a McKinsey & Company management consultant focusing on complex health care issues for Fortune 500 companies. Dr. Haller has published several peer-reviewed articles, presented at numerous scientific conferences, and is co-inventor on multiple patents. Dr. Haller earned his Ph.D. in Biomedical Engineering from The Johns Hopkins University School of Medicine, his M.S. in Chemical Engineering from Cornell University and his B.S. in Biomedical Engineering from The Johns Hopkins University.